COVID-SEROKLIR Trademark

Trademark Overview


On Friday, August 21, 2020, a trademark application was filed for COVID-SEROKLIR with the United States Patent and Trademark Office. The USPTO has given the COVID-SEROKLIR trademark a serial number of 90130724. The federal status of this trademark filing is ABANDONED - FAILURE TO RESPOND OR LATE RESPONSE as of Tuesday, April 12, 2022. This trademark is owned by Kantaro Biosciences LLC. The COVID-SEROKLIR trademark is filed in the Pharmaceutical Products category with the following description:

Diagnostic preparations for medical purposes for use in hospitals; Diagnostic agents, preparations and substances for medical or veterinary purposes; Medical diagnostic reagents and assays for testing and analysis of blood, bodily fluids, biological and cellular samples and specimens; Assays, reagents, media, solutions, buffers and preparations for medical, clinical and diagnostic use; Diagnostic agents for carrying out serologic tests for medical and clinical purposes; Diagnostic reagents for serologic tests of infections for medical and clinical purposes; Diagnostic agents, preparations, substances and diagnostic test kits primarily comprised of material, preparations, assays and reagents and also consisting of vessels, containers and implements for performing serological, molecular PCR, antigen and antibody detection tests, and used for detecting antibodies, enzymes, antigens, diseases, viruses and infections for medical, clinical and research purposes; Kits and components comprised...
covid-seroklir

General Information


Serial Number90130724
Word MarkCOVID-SEROKLIR
Filing DateFriday, August 21, 2020
Status602 - ABANDONED - FAILURE TO RESPOND OR LATE RESPONSE
Status DateTuesday, April 12, 2022
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateNOT AVAILABLE

Trademark Statements


Goods and ServicesDiagnostic preparations for medical purposes for use in hospitals; Diagnostic agents, preparations and substances for medical or veterinary purposes; Medical diagnostic reagents and assays for testing and analysis of blood, bodily fluids, biological and cellular samples and specimens; Assays, reagents, media, solutions, buffers and preparations for medical, clinical and diagnostic use; Diagnostic agents for carrying out serologic tests for medical and clinical purposes; Diagnostic reagents for serologic tests of infections for medical and clinical purposes; Diagnostic agents, preparations, substances and diagnostic test kits primarily comprised of material, preparations, assays and reagents and also consisting of vessels, containers and implements for performing serological, molecular PCR, antigen and antibody detection tests, and used for detecting antibodies, enzymes, antigens, diseases, viruses and infections for medical, clinical and research purposes; Kits and components comprised of assays, reagents, media, solutions, buffers, antibodies, antigens, control materials, membranes, plasma, diagnostic chemicals, calibrators, swabs for medical purposes, plates, vessels, tubes, pipettes, trays, panels, slides, cards and bottles for use in performing medical diagnostic testing for medical or veterinary use; Test kits consisting of medical diagnostic reagents, assays, solutions and buffers for testing in the field of the prevention and treatment of infections, viruses, disorders and diseases; Diagnostic kits comprised of medical diagnostic reagents and assays for testing and analysis of blood, bodily fluids, biological and cellular samples and specimens for use in infection, virus and disease detection, namely, infectious, viral, communicable, blood-borne pathogen, vector-borne, pulmonary, respiratory, inflammatory, immunological, autoimmune, rheumatic and cardiovascular diseases and disorders; Diagnostic test in the nature of medical diagnostic reagents and assays for testing of bodily fluids for antibodies for use in disease detection, namely, SARS-CoV-2, COVID-19, cancer, and infectious, viral, communicable, blood borne pathogen, vector borne, pulmonary, respiratory, inflammatory, immunological, autoimmune, rheumatic and cardiovascular diseases and disorders; Medical and clinical test kits comprised of assays, reagents, media, solutions, buffers and preparations for use in disease detection and monitoring of coronavirus, SARS-CoV-2 and COVID-19; Diagnostic preparations for medical and clinical purposes for detecting the presence of infectious, viral, communicable, blood-borne pathogen, vector-borne, pulmonary, respiratory, inflammatory, immunological, autoimmune, rheumatic and cardiovascular diseases and disorders; Preparations and substances for the diagnosis, prevention and treatment of SARS-CoV-2, COVID-19, and infectious, viral, communicable, blood-borne pathogen, vector-borne, pulmonary, respiratory, inflammatory, immunological, autoimmune, rheumatic and cardiovascular diseases and disorders; all the foregoing related to the detection, diagnosis, testing, prevention and/or treatment of SARS-CoV-2, COVID-19 and antibodies, antigens, diseases, illnesses, viruses, disorders and/or infections related to SARS-CoV-2 or COVID-19

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateThursday, September 24, 2020
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameKantaro Biosciences LLC
Party Type10 - Original Applicant
Legal Entity Type16 - Limited Liability Company
AddressNew York, NY 10036

Trademark Events


Event DateEvent Description
Tuesday, April 12, 2022ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND
Tuesday, April 12, 2022ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND
Tuesday, April 12, 2022ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
Tuesday, September 28, 2021NOTIFICATION OF NON-FINAL ACTION E-MAILED
Tuesday, September 28, 2021NON-FINAL ACTION E-MAILED
Tuesday, September 28, 2021NON-FINAL ACTION WRITTEN
Monday, August 30, 2021ASSIGNED TO EXAMINER
Friday, August 27, 2021TEAS/EMAIL CORRESPONDENCE ENTERED
Thursday, August 26, 2021CORRESPONDENCE RECEIVED IN LAW OFFICE
Thursday, August 26, 2021TEAS RESPONSE TO OFFICE ACTION RECEIVED
Saturday, March 6, 2021NOTIFICATION OF NON-FINAL ACTION E-MAILED
Saturday, March 6, 2021NON-FINAL ACTION E-MAILED
Saturday, March 6, 2021NON-FINAL ACTION WRITTEN
Monday, February 22, 2021ASSIGNED TO EXAMINER
Thursday, September 24, 2020NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Tuesday, August 25, 2020NEW APPLICATION ENTERED IN TRAM